Navigation Links
Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
Date:3/4/2013

hibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso™ trials investigating this regimen are now underway.

Faldaprevir and BI 207127 are investigational compounds and not approved by the FDA. Their safety and efficacy have not been established.

Hepatitis C is a blood-born infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, an estimated 4.1 million Americans have been infected with HCV, of which approximately 3.2 million have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, accounting for 15,000 deaths in the United States in 2007.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The Competitive Intelligence (CI) function is ... CI leaders who adjust will succeed, and those who ... Best Practices, LLC study CI leaders from 32 biopharmaceutical ... - Use secondary research whenever possible - it,s ... - Internal staff who are creative thinkers provide the ...
(Date:8/29/2014)... -- Pomerantz LLP has filed a class action lawsuit ... EDAP ) and certain of its officers.  The ... District of New York , and ... consisting of all persons or entities who purchased EDAP ... inclusive (the "Class Period"). This class action seeks to recover ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... announced the initiation of a landmark Phase 2 ... developed to improve neurological function in patients with ... In accordance with its internal focus on scientific ... at a peer-attended symposium at the American Spinal ...
... April 23, 2012 Medela convened the 7th ... on April 20-21, 2012. The annual event, attended ... lactation consultants, highlighted the latest insights into breastfeeding ... supporting breastfeeding women and their families through research ...
Cached Medicine Technology:Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 2Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 3Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 2Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 3
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Village, IL (PRWEB) August 29, 2014 ... in hearing wellness solutions, is on its way to ... at the San Diego Convention Center to exhibit and ... who work in high-noise industrial environments. Etymotic’s safety earphones ... hottest wearable technology devices at the show. , ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 ... “The Safety Chick” who profiled a handful of ... Earphones from Etymotic Research. This year, many schools ... and Etymotic, an innovator of hearing wellness solutions, ... Their ETY•Kids Safe-Listening Earphones, offered in yellow, pink ...
(Date:8/29/2014)... London, UK (PRWEB) August 29, 2014 ... growing ones in the in-vitro diagnostics industry; it is ... The growth is driven by the ongoing spread of ... a primary factor associated with the upsurge of opportunistic ... diagnostic; and a broader availability of immunosuppressive medicines. Although ...
(Date:8/29/2014)... Edvance360, a leading provider of eLearning ... teaching, as well as 2011 winner and six-time-finalist for ... System, announced that Brooke Education Services, Northwest Academy, Typewell, ... Advertising Bureau of Canada (IAB Canada), StarSVCS, and HMG ... delighted to welcome each new client to the growing ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 3Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2
... Prevention efforts ,have run out of steam, expert says, , , ... risk of dying prematurely? Don,t smoke and keep a healthy ... about one in five deaths among U.S. adults, according to ... to be linked with premature death, the magnitude of the ...
... East and the Asia-Pacific region , , TUESDAY, April 28 (HealthDay ... in the United States has doubled to 40, U.S. health ... a New York City high school that had previously reported ... Tuesday were listing the number of U.S. cases at 50, ...
... Trends Suggest These Agents Will Face Greater Use of ... on Commercial Health Plans, According to a New Report ... N.J., April 28 HealthLeaders-InterStudy and Fingertip ... antihypertensives are expected to face tougher formulary restrictions. According ...
... Doors with Offices in New York ... 28 Diversified Agency Services (DAS) today announced the launch ... New York and London. TogoRun specializes in healthcare, pharmaceutical ... roster includes many of the world,s leading healthcare brands.The new ...
... by Troops Coming Home from WarCAMBRIDGE, Mass., April 28 ... Veterans Affairs Appropriations Subcommittee on behalf of ALS patients, ... (ALS TDI), last Thursday. Dr. Appel urged congress ... such as the one at ALS TDI. Dr. ...
... 28 Verathon(R) is pleased to announce the new ... with Urologists in mind, the BVM 9500 measures both ... noninvasively to help diagnose bladder dysfunction, including BPH (benign ... new addition to the BladderScan(R) BVI 9000 series made ...
Cached Medicine News:Health News:1 in 5 U.S. Deaths Attributed to Smoking, High BP 2Health News:Some Reports Put Number of U.S. Swine Flu Cases at 50 2Health News:Some Reports Put Number of U.S. Swine Flu Cases at 50 3Health News:Some Reports Put Number of U.S. Swine Flu Cases at 50 4Health News:Some Reports Put Number of U.S. Swine Flu Cases at 50 5Health News:Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions 2Health News:Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions 3Health News:Diversified Agency Services Network Launches TogoRun(TM), A New Global Healthcare Communications Agency 2Health News:Diversified Agency Services Network Launches TogoRun(TM), A New Global Healthcare Communications Agency 3Health News:Diversified Agency Services Network Launches TogoRun(TM), A New Global Healthcare Communications Agency 4Health News:ALS Therapy Development Institute Delivers Impassioned Testimony to Congressional Subcommittee on Veterans Affairs 2Health News:ALS Therapy Development Institute Delivers Impassioned Testimony to Congressional Subcommittee on Veterans Affairs 3Health News:Verathon(R) Introduces BladderScan(R) BVM 9500 Bladder Volume Instrument To Help Urologists Diagnose Bladder Dysfunction 2Health News:Verathon(R) Introduces BladderScan(R) BVM 9500 Bladder Volume Instrument To Help Urologists Diagnose Bladder Dysfunction 3
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... To help cardiologists meet the ... Toshiba introduces the high performance Infinix ... solutions combine easy-to-use controls, one-touch operations, ... to optimize workflow and allow physicians ...
Cardiac 5-Axis Bi-plane: Infinix CF-i/BP...
... on the promise of Flat Panel ... outstanding image quality, at lower doses, ... small devices and structures. The new ... at lower dose than other systems ...
Medicine Products: